Medical Devices

A new trial for advanced liver cancer tests visugromab, a drug aiming to overcome immunotherapy resistance and reverse debilitating cancer-related wasting.

With diagnostic sales fueling a diverse therapeutic arsenal, Telix reaffirms blockbuster guidance and advances pivotal trials for prostate, brain, and kidney cancers.

A new award-winning serum promises 'glass skin' and enhances injectable results, tapping into a multi-billion dollar market. Here's the science behind it.

Nano Dimension sells its AME product line to cut costs, while buyer Inspira Technologies makes a high-risk pivot from medical devices to quantum computing.

Vyome is set to present promising Phase 2 data for VT-1953, a first-in-class treatment for a debilitating cancer complication with no approved drugs.

Amid financial headwinds, radiation therapy firm Accuray appoints a proven sales leader to spearhead a critical commercial transformation.

A long-acting ketamine injection shows promise in treating severe depression without the harsh side effects and monitoring, potentially expanding access for millions.

With record revenue and A-list fans, British MedTech firm LYMA is doubling down on the US market, blending clinical data with celebrity appeal.

New preclinical data for ATNM-400 and Actimab-A shows promise for treating resistant solid tumors and AML, highlighting a new frontier in cancer therapy.

A major lab expansion in Massachusetts aims to slash preclinical timelines for the most promising new cancer treatments, including advanced radiotherapies.

A $10M investment from BVF Partners propels Entera Bio’s revolutionary oral osteoporosis drug into a pivotal Phase 3 trial, a major step for patients.

A pivotal clinical trial for PMM2-CDG, a devastating genetic disorder with no approved treatments, has completed enrollment, offering hope to thousands.

Dr. Amit Singal, a leading hepatologist, joins Curve Biosciences as CMO, aiming to leverage AI to find chronic liver disease before it becomes incurable.

After 40 years as a silent partner to global brands, Intercon Chemical is launching its own high-stakes medical cleaning lines to meet new safety standards.

A novel triple-action topical spray for male pattern baldness enters a pivotal clinical trial, potentially disrupting a multi-billion dollar market.

After a period of limited availability, the Ellipsys Vascular Access System is set for a 2026 relaunch, promising a less invasive option for dialysis patients.

The full commercial launch of the Aeros Modular Stem System brings advanced 3D printing and a novel surgical approach to the competitive ankle replacement market.

AvenCell has dosed the first patient with AVC-203, a novel allogeneic CAR-T therapy, aiming to make advanced cancer treatment more accessible and effective.

Indian pharma giant Lupin acquires European ophthalmology specialist VISUfarma, gaining a major foothold in a market fueled by an aging population.

As cancer strikes younger patients, a new partnership aims to find the disease before symptoms start. But is this new technology ready for prime time?